Northwell Health, New York, New York, USA.
Division of Kidney Diseases and Hypertension, Glomerular Center at Northwell Health, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York, USA.
Cardiorenal Med. 2024;14(1):281-293. doi: 10.1159/000539075. Epub 2024 Apr 29.
The evolving landscape of cancer treatments has introduced new challenges, particularly related to adverse events associated with chemotherapeutic agents. To address these challenges, the fields of cardio-oncology and onco-nephrology have arisen, focusing on the management of cardiotoxicity and nephrotoxicity attributable to anti-cancer drugs.
Numerous intersections between these disciplines exist, including onco-hypertension (HTN) and cardiorenal toxicities induced by chemotherapeutic agents. Additionally, immune checkpoint inhibitors (ICIs) may cause myocarditis and nephritis. This paper aimed to explore the intersection between cardio-oncology and onco-nephrology. A detailed review will be undertaken, focusing on onco-HTN and the cardiorenal toxicities of chemotherapeutic agents, with a specific emphasis on the adverse effects associated with ICIs.
Multidisciplinary collaboration among oncologists, cardiologists, nephrologists, and other healthcare professionals is crucial for developing tailored approaches to optimize treatment efficacy while minimizing the risk of cardiovascular and renal complications, ultimately enhancing patient outcomes in modern oncology practice.
癌症治疗领域的不断发展带来了新的挑战，特别是与化疗药物相关的不良事件。为了应对这些挑战，出现了肿瘤心脏病学和肿瘤肾脏病学领域，专注于管理癌症药物引起的心脏毒性和肾毒性。
这些学科之间存在许多交叉点，包括肿瘤相关性高血压（HTN）和化疗药物引起的心肾毒性。此外，免疫检查点抑制剂（ICI）可能导致心肌炎和肾炎。本文旨在探讨肿瘤心脏病学和肿瘤肾脏病学之间的交叉点。将进行详细的审查，重点关注肿瘤相关性高血压和化疗药物的心脏毒性，特别关注与 ICI 相关的不良反应。
肿瘤学家、心脏病学家、肾脏病学家和其他医疗保健专业人员之间的多学科合作对于制定个性化方法至关重要，以优化治疗效果，同时最大限度地降低心血管和肾脏并发症的风险，最终提高现代肿瘤学实践中的患者结局。
